A5026132340- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Breast Lesions and Carcinomas
- Estrogen and related hormone effects
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Advanced Biosensing Techniques and Applications
- Epigenetics and DNA Methylation
- Advanced biosensing and bioanalysis techniques
- Ferrocene Chemistry and Applications
- Peptidase Inhibition and Analysis
- Global Cancer Incidence and Screening
- Cancer Immunotherapy and Biomarkers
- Histone Deacetylase Inhibitors Research
- Radiopharmaceutical Chemistry and Applications
- Cancer-related Molecular Pathways
- Cancer Cells and Metastasis
- Chronic Lymphocytic Leukemia Research
- BRCA gene mutations in cancer
- Gene expression and cancer classification
- Genomics and Chromatin Dynamics
- Nanoparticle-Based Drug Delivery
Dana-Farber Cancer Institute
2016-2025
Dana-Farber/Harvard Cancer Center
2025
Harvard University
2013-2025
Alliance Foundation Trials
2018-2025
CancerCare
2021-2025
Dana-Farber Brigham Cancer Center
2013-2024
Brigham and Women's Hospital
2016-2024
Yale Cancer Center
2024
Broad Institute
2024
Alliance for Clinical Trials in Oncology
2016-2024
Purpose To retrospectively evaluate the pattern of recurrence and outcome node-negative breast cancer (BC) according to major subtypes. Patients Methods In all, 1,951 patients with node-negative, early-stage BC randomly assigned in International Breast Cancer Study Group Trials VIII IX centrally reviewed pathology data were included. subtypes defined as triple negative (TN; n = 310), human epidermal growth factor receptor 2 (HER2) positive (n 369), hormone high (luminal B–like [LB-like];...
Invasive lobular breast cancer (ILBC) is the second most common histologic subtype after invasive ductal (IDBC). Despite clinical and pathologic differences, ILBC still treated as IDBC. We aimed to identify genomic alterations in with potential implications.From an initial 630 primary tumors, we interrogated oncogenic substitutions insertions deletions of 360 genes genome-wide copy number aberrations 413 170 samples, respectively, correlated those findings clinicopathologic outcome...
Purpose To document the rate and outcome of trastuzumab-associated cardiac dysfunction in patients following 1 or 2 years adjuvant therapy. Patients Methods The Herceptin Adjuvant (HERA) trial is a three-arm, randomized comparing year trastuzumab with observation 5,102 human epidermal growth factor receptor (HER2) –positive early-stage breast cancer. Cardiac function was closely monitored. Eligible had left ventricular ejection fraction (LVEF) ≥ 55% at study entry neoadjuvant chemotherapy...
To evaluate the relative effectiveness of letrozole compared with tamoxifen for patients invasive ductal or lobular carcinoma.
Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, potential value of adding palbociclib to endocrine therapy hormone receptor-positive cancer has not been confirmed.
Abstract Intratumor heterogeneity is postulated to cause therapeutic resistance. To prospectively assess the impact of HER2 (ERBB2) on response HER2-targeted therapy, we treated 164 patients with centrally confirmed HER2-positive early-stage breast cancer neoadjuvant trastuzumab emtansine plus pertuzumab. was assessed pretreatment biopsies from two locations each tumor. heterogeneity, defined as an area ERBB2 amplification in >5% but <50% tumor cells, or a HER2-negative by...
Primary analyses of the phase III BrighTNess trial showed addition carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved pathological complete response (pCR) rates with manageable acute toxicity in patients triple-negative breast cancer (TNBC). Here, we report 4.5-year follow-up data from trial.Women untreated stage II-III TNBC were randomized (2 : 1 1) paclitaxel (weekly for 12 doses) plus: (i) (every 3 weeks four cycles) plus (twice daily); (ii) placebo; or...
PURPOSE In light of evolving evidence that some patients with node-positive estrogen receptor–positive (ER+) disease may receive less benefit from chemotherapy, this study reports 12-year outcomes the C9741 trial overall, and by sensitivity to endocrine therapy (SET2,3) test index, a biomarker measuring transcriptional activity, identify most likely dose-dense chemotherapy. METHODS all, 1,973 were randomly assigned versus conventional Hazard ratios (HRs) for prognosis predictive interaction...
Importance Triple-negative breast cancer is an aggressive subtype with a high incidence in young patients, non-Hispanic Black women, and risk of progression to metastatic cancer, devastating sequela 12- 18-month life expectancy. Until recently, one strategy for treating early-stage triple-negative was chemotherapy after surgery. However, it not known whether the addition immune therapy postsurgery would be beneficial. Objective To evaluate form atezolizumab postoperative patients high-risk...
Abstract Breast cancer is a molecularly, biologically and clinically heterogeneous group of disorders. Understanding this diversity essential to improving diagnosis optimizing treatment. Both genetic acquired epigenetic abnormalities participate in cancer, but the involvement epigenome breast its contribution complexity disease are still poorly understood. By means DNA methylation profiling 248 tissues, we have highlighted existence previously unrecognized groups that go beyond currently...
Neoadjuvant systemic therapy (NST) is often administered to enable breast-conserving (BCT) in stages II III breast cancer.To prospectively evaluate the role of NST conversion from BCT ineligibility eligibility and assess association response NST, germline BRCA (gBRCA) status, region treatment with surgical choice women triple-negative cancer (TNBC).This prespecified secondary analysis a multicentered, phase 3, double-blind, randomized clinical trial (BrighTNess) enrolled 634 eligible across...
502 Background: HER2 targeted therapy without chemotherapy may be insufficient to completely eradicate a HER2+ cancer in cases of significant intratumor heterogeneity (ITH-HER2). Methods: We conducted single-arm phase II study enrolling centrally confirmed breast cancer. Pts received 6 cycles T-DM1 plus Pertuzumab before surgery. Central ITH-HER2 was assessed on baseline ultrasound-guided core biopsies from 2 distinct areas each tumor (3 cores/site). defined as at least one the six...
Importance Patients with early-stage ERBB2 (formerly HER2 )–positive breast cancer ( + BC) who experience a pathologic complete response (pCR) after receiving neoadjuvant therapy have favorable survival outcomes. Predicting the likelihood of pCR may help optimize therapy. Objective To test ability HER2DX assay to predict in patients BC are deescalated Design, Setting, and Participants In this diagnostic/prognostic study, was administered on pretreatment tumor biopsy samples from enrolled...
•HER2DX assay is highly reproducible and robust intra- inter-laboratories.•HER2DX proved performance for different protocol variations including platforms.•HER2DX has proven technical reliability in predicting outcomes early-stage HER2-positive breast cancer. BackgroundHER2DX, a multianalyte genomic test, been clinically validated to predict cancer recurrence risk (relapse score), the probability of achieving pathological complete response post-neoadjuvant therapy (pCR likelihood individual...